News | Contrast Media | July 03, 2023

Preferential use of pulmonary MR angiography (MRA) for diagnosing pulmonary embolus (PE) in the general population helped conserve iodinated contrast media during the 2022 shortage 

Preferential use of pulmonary MR angiography (MRA) for diagnosing pulmonary embolus (PE) in the general population helped conserve iodinated contrast media during the 2022 shortage

Patient was found to have deep vein thrombosis. Gadolinium-enhanced MRA was performed to assess for pulmonary embolus (PE). Coronal contrast-enhanced T1-weighted images in pulmonary arterial phase (A) and low flip-angle delayed phase (B) show PE (arrows, A and B). Delayed-phase image also shows cardiac chamber (star) and ascending thoracic aorta (chevron). Multiphase acquisition of MRA during inflow and outflow of contrast agent from pulmonary arteries is in distinction to single acquisition of CTA and may facilitate obtaining optimal enhancement of pulmonary arteries. Image courtesy of AJR 


July 3, 2023 — According to an accepted manuscript published in ARRS’ own American Journal of Roentgenology (AJR), preferential use of pulmonary MR angiography (MRA) for diagnosing pulmonary embolus (PE) in the general population helped conserve iodinated contrast media during the 2022 shortage. 

“This single-center experience demonstrates use of pulmonary MRA as a practical substitute for pulmonary CTA in emergency settings,” concluded lead investigator Jitka Starekova, MD, from the radiology department of the University of Wisconsin in Madison.   

Starekova et al.’s study included all CTA and MRA examinations performed to exclude PE at their large academic medical center (University of Wisconsin-Madison Hospital and Clinics) from April 1 through July 31 (18 weekly periods) in:   

2019 (before the COVID-19 pandemic and contrast media shortage), 

2021 (during the pandemic, though before the shortage), 

2022 (during both the pandemic, as well as the shortage). 

To help preserve iodinated contrast media, from early May through mid-July of 2022, MRA served as the preferred test for PE diagnosis. Upon reviewing CTA and MRA reports, Starekova and her AJR colleagues estimated iodinated contrast media savings via preferential MRA usage. 

Ultimately, preferred use of pulmonary MRA to diagnosis PE among the general population conserved (from April 1 to July 31, 2022) an estimated 27 liters of iohexol (Omnipaque) 350mg/ml. During weeks 8-11, more MRA examinations (range, 45-63) than CTA examinations (range, 27-46) were performed. 

Noting their AJR accepted manuscript evaluated MRA for PE diagnosis in “an all-comer real-world setting,” the present study also includes a larger sample size in comparison to previous research. 

For more information: www.arrs.org


Related Content

News | Contrast Agents

June 15, 2026 – Bayer has announced that the U.S. Food and Drug Administration (FDA) approved Ambelvist (gadoquatrane) ...

Time June 16, 2026
arrow
News | Magnetic Resonance Imaging (MRI)

June 9, 2026 — An investigator at the Icahn School of Medicine at Mount Sinai has received international recognition for ...

Time June 15, 2026
arrow
News | PET-MRI

June 10, 2026 — UTHealth Houston has launched a state-of-the-art PET/MRI imaging service, bringing together two advanced ...

Time June 12, 2026
arrow
News | Innovative Hospitals

May 27, 2026 — Nearly two years after announcing plans for a “real-world” academic-industrial collaboration, GE ...

Time June 03, 2026
arrow
News | Nuclear Imaging

June 1, 2026 — At the 2026 Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting, GE HealthCare will ...

Time June 02, 2026
arrow
News | Ultrasound Imaging

May 26, 2026 — A soft, wearable ultrasound patch that can continuously monitor a fetus for hours at a time — and it can ...

Time May 27, 2026
arrow
News | Cardiac Imaging

May 21, 2026 — A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s ...

Time May 22, 2026
arrow
News | Radiology Imaging

May 18, 2026 — DICO, a company specializing in the creation of distributed diagnostic infrastructure for radiology, has ...

Time May 19, 2026
arrow
News | FDA

May 18, 2026 — ACIST Medical Systems, a Bracco company, has received U.S. Food and Drug Administration (FDA) clearance ...

Time May 18, 2026
arrow
News | Radiopharmaceuticals and Tracers

May 7, 2026 — Bayer has announced positive topline results from the Phase III REVEAL study, an investigator-initiated ...

Time May 08, 2026
arrow
Subscribe Now